Methallenestril

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Methallenestril
Accession Number
DB13143
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
  • b-ethyl-6-methoxy-a,a-dimethyl-2-naphthalenepropionic acid
International/Other Brands
Vallestril
Categories
UNII
XL025389JS
CAS number
517-18-0
Weight
Average: 286.371
Monoisotopic: 286.156894568
Chemical Formula
C18H22O3
InChI Key
KHLJKRBMZVNZOC-MRXNPFEDSA-N
InChI
InChI=1S/C18H22O3/c1-5-16(18(2,3)17(19)20)14-7-6-13-11-15(21-4)9-8-12(13)10-14/h6-11,16H,5H2,1-4H3,(H,19,20)/t16-/m1/s1
IUPAC Name
(3R)-3-(6-methoxynaphthalen-2-yl)-2,2-dimethylpentanoic acid
SMILES
CC[C@H](C1=CC=C2C=C(OC)C=CC2=C1)C(C)(C)C(O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Methallenestril.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Methallenestril.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Methallenestril.Experimental, Illicit
AbciximabMethallenestril may decrease the anticoagulant activities of Abciximab.Approved
AceclofenacAceclofenac may increase the thrombogenic activities of Methallenestril.Approved, Investigational
AcenocoumarolMethallenestril may decrease the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenAcetaminophen may increase the thrombogenic activities of Methallenestril.Approved
Acetylsalicylic acidAcetylsalicylic acid may increase the thrombogenic activities of Methallenestril.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Methallenestril.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Methallenestril.Experimental, Investigational
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be increased when it is combined with Methallenestril.Experimental, Investigational
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Methallenestril.Approved
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Methallenestril.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the thrombogenic activities of Methallenestril.Approved
AnastrozoleThe therapeutic efficacy of Anastrozole can be decreased when used in combination with Methallenestril.Approved, Investigational
AncrodMethallenestril may decrease the anticoagulant activities of Ancrod.Approved, Investigational
AndrostenedioneThe serum concentration of Androstenedione can be increased when it is combined with Methallenestril.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Methallenestril.Investigational
anecortave acetateThe serum concentration of anecortave acetate can be increased when it is combined with Methallenestril.Investigational
Anthrax immune globulin humanMethallenestril may increase the thrombogenic activities of Anthrax immune globulin human.Approved
AntipyrineAntipyrine may increase the thrombogenic activities of Methallenestril.Approved, Investigational
Antithrombin III humanMethallenestril may decrease the anticoagulant activities of Antithrombin III human.Approved
AntrafenineAntrafenine may increase the thrombogenic activities of Methallenestril.Approved
ApixabanMethallenestril may decrease the anticoagulant activities of Apixaban.Approved
ArdeparinMethallenestril may decrease the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanMethallenestril may decrease the anticoagulant activities of Argatroban.Approved, Investigational
AtamestaneThe serum concentration of Atamestane can be increased when it is combined with Methallenestril.Investigational
BalsalazideBalsalazide may increase the thrombogenic activities of Methallenestril.Approved, Investigational
BecaplerminMethallenestril may decrease the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Methallenestril.Approved, Investigational
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Methallenestril.Approved, Vet Approved
BivalirudinMethallenestril may decrease the anticoagulant activities of Bivalirudin.Approved, Investigational
BromfenacBromfenac may increase the thrombogenic activities of Methallenestril.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Methallenestril.Approved
BufexamacBufexamac may increase the thrombogenic activities of Methallenestril.Approved, Experimental
Capromab pendetideMethallenestril may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CapsaicinCapsaicin may increase the thrombogenic activities of Methallenestril.Approved
CarprofenCarprofen may increase the thrombogenic activities of Methallenestril.Approved, Vet Approved, Withdrawn
CelecoxibCelecoxib may increase the thrombogenic activities of Methallenestril.Approved, Investigational
CertoparinMethallenestril may decrease the anticoagulant activities of Certoparin.Approved, Investigational
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Methallenestril.Approved
ChlorphenesinChlorphenesin may increase the thrombogenic activities of Methallenestril.Approved, Vet Approved, Withdrawn
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the thrombogenic activities of Methallenestril.Approved
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Methallenestril.Approved, Investigational
CimicoxibCimicoxib may increase the thrombogenic activities of Methallenestril.Investigational
CisplatinCisplatin may increase the thrombogenic activities of Methallenestril.Approved
Citric AcidMethallenestril may decrease the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Methallenestril.Approved, Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Methallenestril.Approved
ClobetasoneThe serum concentration of Clobetasone can be increased when it is combined with Methallenestril.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Methallenestril.Approved
Clodronic AcidClodronic Acid may increase the thrombogenic activities of Methallenestril.Approved, Investigational, Vet Approved
Conestat alfaMethallenestril may increase the thrombogenic activities of Conestat alfa.Approved, Investigational
Cortexolone 17α-propionateThe serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Methallenestril.Investigational
CorticosteroneThe serum concentration of Corticosterone can be increased when it is combined with Methallenestril.Experimental
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Methallenestril.Approved, Investigational
Dabigatran etexilateMethallenestril may decrease the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinMethallenestril may decrease the anticoagulant activities of Dalteparin.Approved
DanaparoidMethallenestril may decrease the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanMethallenestril may decrease the anticoagulant activities of Darexaban.Investigational
DeflazacortThe serum concentration of Deflazacort can be increased when it is combined with Methallenestril.Approved, Investigational
DesirudinMethallenestril may decrease the anticoagulant activities of Desirudin.Approved
DesonideThe serum concentration of Desonide can be increased when it is combined with Methallenestril.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Methallenestril.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Methallenestril.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Methallenestril.Experimental, Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Methallenestril.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Methallenestril.Vet Approved
DexibuprofenDexibuprofen may increase the thrombogenic activities of Methallenestril.Approved, Investigational
DexketoprofenDexketoprofen may increase the thrombogenic activities of Methallenestril.Approved, Investigational
DextranMethallenestril may decrease the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DiclofenacDiclofenac may increase the thrombogenic activities of Methallenestril.Approved, Vet Approved
DicoumarolMethallenestril may decrease the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Methallenestril.Approved
DiflunisalDiflunisal may increase the thrombogenic activities of Methallenestril.Approved, Investigational
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Methallenestril.Approved, Investigational, Withdrawn
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Methallenestril.Approved
DrospirenoneDrospirenone may increase the thrombogenic activities of Methallenestril.Approved
DroxicamDroxicam may increase the thrombogenic activities of Methallenestril.Withdrawn
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Methallenestril.Approved
Edetic AcidMethallenestril may decrease the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMethallenestril may decrease the anticoagulant activities of Edoxaban.Approved
EnoxaparinMethallenestril may decrease the anticoagulant activities of Enoxaparin.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Methallenestril.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Methallenestril.Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Methallenestril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Methallenestril.Approved
EtanerceptEtanercept may increase the thrombogenic activities of Methallenestril.Approved, Investigational
Ethyl biscoumacetateMethallenestril may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the thrombogenic activities of Methallenestril.Approved, Investigational, Vet Approved
EtoricoxibEtoricoxib may increase the thrombogenic activities of Methallenestril.Approved, Investigational
ExemestaneThe therapeutic efficacy of Exemestane can be decreased when used in combination with Methallenestril.Approved, Investigational
FenoprofenFenoprofen may increase the thrombogenic activities of Methallenestril.Approved
Ferulic acidMethallenestril may decrease the anticoagulant activities of Ferulic acid.Experimental
Fish oilFish oil may increase the thrombogenic activities of Methallenestril.Approved, Nutraceutical
FluasteroneThe serum concentration of Fluasterone can be increased when it is combined with Methallenestril.Investigational
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Methallenestril.Approved, Investigational
FluindioneMethallenestril may decrease the anticoagulant activities of Fluindione.Approved, Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Methallenestril.Approved, Vet Approved
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Methallenestril.Approved, Investigational
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Methallenestril.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Methallenestril.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Methallenestril.Approved, Withdrawn
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Methallenestril.Approved, Investigational
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Methallenestril.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Methallenestril.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Methallenestril.Approved
FlurbiprofenFlurbiprofen may increase the thrombogenic activities of Methallenestril.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Methallenestril.Approved, Experimental, Investigational
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Methallenestril.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Methallenestril.Approved
FondaparinuxMethallenestril may decrease the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumMethallenestril may decrease the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Methallenestril.Approved, Investigational, Withdrawn
GabexateMethallenestril may decrease the anticoagulant activities of Gabexate.Investigational
GinsengGinseng may increase the thrombogenic activities of Methallenestril.Approved, Investigational, Nutraceutical
HalcinonideThe serum concentration of Halcinonide can be increased when it is combined with Methallenestril.Approved, Investigational, Withdrawn
HE3286The serum concentration of HE3286 can be increased when it is combined with Methallenestril.Investigational
HeparinMethallenestril may decrease the anticoagulant activities of Heparin.Approved, Investigational
Human C1-esterase inhibitorMethallenestril may increase the thrombogenic activities of Human C1-esterase inhibitor.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methallenestril.Approved, Investigational
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Methallenestril.Approved, Vet Approved
IbuprofenIbuprofen may increase the thrombogenic activities of Methallenestril.Approved
IcosapentIcosapent may increase the thrombogenic activities of Methallenestril.Approved, Nutraceutical
IdraparinuxMethallenestril may decrease the anticoagulant activities of Idraparinux.Investigational
IndomethacinIndomethacin may increase the thrombogenic activities of Methallenestril.Approved, Investigational
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Methallenestril.Investigational
KetoprofenKetoprofen may increase the thrombogenic activities of Methallenestril.Approved, Vet Approved
KetorolacKetorolac may increase the thrombogenic activities of Methallenestril.Approved
LenalidomideMethallenestril may increase the thrombogenic activities of Lenalidomide.Approved
LepirudinMethallenestril may decrease the anticoagulant activities of Lepirudin.Approved
LetaxabanMethallenestril may decrease the anticoagulant activities of Letaxaban.Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Methallenestril.Approved
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Methallenestril.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Methallenestril.Approved
LornoxicamLornoxicam may increase the thrombogenic activities of Methallenestril.Approved, Investigational
LoteprednolThe serum concentration of Loteprednol can be increased when it is combined with Methallenestril.Approved
LumiracoxibLumiracoxib may increase the thrombogenic activities of Methallenestril.Approved, Investigational
Magnesium salicylateMagnesium salicylate may increase the thrombogenic activities of Methallenestril.Approved
ME-609The serum concentration of ME-609 can be increased when it is combined with Methallenestril.Investigational
Meclofenamic acidMeclofenamic acid may increase the thrombogenic activities of Methallenestril.Approved, Vet Approved
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Methallenestril.Approved
Mefenamic acidMefenamic acid may increase the thrombogenic activities of Methallenestril.Approved
MelagatranMethallenestril may decrease the anticoagulant activities of Melagatran.Experimental
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Methallenestril.Vet Approved
MeloxicamMeloxicam may increase the thrombogenic activities of Methallenestril.Approved, Vet Approved
MesalazineMesalazine may increase the thrombogenic activities of Methallenestril.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Methallenestril.Approved, Vet Approved
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Methallenestril.Approved, Vet Approved
MorniflumateMorniflumate may increase the thrombogenic activities of Methallenestril.Approved
NabumetoneNabumetone may increase the thrombogenic activities of Methallenestril.Approved
NadroparinMethallenestril may decrease the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatMethallenestril may decrease the anticoagulant activities of Nafamostat.Approved, Investigational
NaproxenNaproxen may increase the thrombogenic activities of Methallenestril.Approved, Vet Approved
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Methallenestril.Investigational
NepafenacNepafenac may increase the thrombogenic activities of Methallenestril.Approved, Investigational
Niflumic AcidNiflumic Acid may increase the thrombogenic activities of Methallenestril.Approved
NimesulideNimesulide may increase the thrombogenic activities of Methallenestril.Approved, Investigational, Withdrawn
Oleoyl-estroneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Methallenestril.Investigational
OspemifeneThe risk or severity of adverse effects can be increased when Methallenestril is combined with Ospemifene.Approved, Investigational
OtamixabanMethallenestril may decrease the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the thrombogenic activities of Methallenestril.Approved
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Methallenestril.Approved
ParecoxibParecoxib may increase the thrombogenic activities of Methallenestril.Approved
Pentaerythritol TetranitrateMethallenestril may decrease the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateMethallenestril may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
PhenindioneMethallenestril may decrease the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonMethallenestril may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazonePhenylbutazone may increase the thrombogenic activities of Methallenestril.Approved, Vet Approved
PiroxicamPiroxicam may increase the thrombogenic activities of Methallenestril.Approved, Investigational
PomalidomidePomalidomide may increase the thrombogenic activities of Methallenestril.Approved
Potassium CitrateMethallenestril may decrease the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Methallenestril.Approved, Investigational, Nutraceutical
Prasterone sulfateThe serum concentration of Prasterone sulfate can be increased when it is combined with Methallenestril.Investigational
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Methallenestril.Approved, Investigational
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Methallenestril.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Methallenestril.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Methallenestril.Approved, Experimental, Investigational
Protein CMethallenestril may decrease the anticoagulant activities of Protein C.Approved
Protein S humanMethallenestril may decrease the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeMethallenestril may decrease the anticoagulant activities of Protocatechualdehyde.Approved
ResveratrolResveratrol may increase the thrombogenic activities of Methallenestril.Approved, Experimental, Investigational
ReviparinMethallenestril may decrease the anticoagulant activities of Reviparin.Approved, Investigational
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Methallenestril.Approved
RivaroxabanMethallenestril may decrease the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the thrombogenic activities of Methallenestril.Approved, Investigational, Withdrawn
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Methallenestril.Approved, Investigational
Salicylic acidSalicylic acid may increase the thrombogenic activities of Methallenestril.Approved, Investigational, Vet Approved
SalsalateSalsalate may increase the thrombogenic activities of Methallenestril.Approved
SeliciclibSeliciclib may increase the thrombogenic activities of Methallenestril.Investigational
Sodium CitrateMethallenestril may decrease the anticoagulant activities of Sodium Citrate.Approved, Investigational
SomatotropinThe therapeutic efficacy of Somatotropin can be decreased when used in combination with Methallenestril.Approved, Investigational
SulfasalazineSulfasalazine may increase the thrombogenic activities of Methallenestril.Approved
SulindacSulindac may increase the thrombogenic activities of Methallenestril.Approved, Investigational
SulodexideMethallenestril may decrease the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenSuprofen may increase the thrombogenic activities of Methallenestril.Approved, Withdrawn
TalniflumateTalniflumate may increase the thrombogenic activities of Methallenestril.Approved
TenoxicamTenoxicam may increase the thrombogenic activities of Methallenestril.Approved
ThalidomideMethallenestril may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Methallenestril.Approved
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Methallenestril.Approved
Tiaprofenic acidTiaprofenic acid may increase the thrombogenic activities of Methallenestril.Approved
TipranavirMethallenestril may increase the dermatologic adverse activities of Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Methallenestril.Approved, Withdrawn
TolmetinTolmetin may increase the thrombogenic activities of Methallenestril.Approved
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Methallenestril.Approved, Vet Approved
Trolamine salicylateTrolamine salicylate may increase the thrombogenic activities of Methallenestril.Approved
TroxerutinMethallenestril may decrease the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe serum concentration of Ulobetasol can be increased when it is combined with Methallenestril.Approved
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Methallenestril.Approved, Investigational
ValdecoxibValdecoxib may increase the thrombogenic activities of Methallenestril.Approved, Investigational, Withdrawn
Vitamin CThe serum concentration of Methallenestril can be increased when it is combined with Vitamin C.Approved, Nutraceutical
WarfarinMethallenestril may decrease the anticoagulant activities of Warfarin.Approved
XimelagatranMethallenestril may decrease the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
59084697
PubChem Substance
347829260
ChemSpider
34995295
Wikipedia
Methallenestril
ATC Codes
G03CC03 — MethallenestrilG03CB03 — Methallenestril

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00102 mg/mLALOGPS
logP4.69ALOGPS
logP4.72ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)4.53ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity83.11 m3·mol-1ChemAxon
Polarizability32.23 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Not Available
Direct Parent
Naphthalenes
Alternative Parents
Anisoles / Alkyl aryl ethers / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Naphthalene / Phenol ether / Anisole / Alkyl aryl ether / Monocarboxylic acid or derivatives / Ether / Carboxylic acid / Carboxylic acid derivative / Organic oxygen compound / Organic oxide
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available

Drug created on November 04, 2016 15:36 / Updated on June 02, 2018 08:46